




Docket No.: B0801.70280US01
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Arthur O. Tzianabos et al.
Serial No.: 10/814,620
Confirmation No.: 5444
Filed: March 31, 2004
For: ZWITTERIONIC IMMUNOMODULATORS FOR THE
TREATMENT OF ASTHMA AND ALLERGY
Examiner: N. M. Rooney
Art Unit: 1644

Certificate of Mailing Under 37 CFR 1.8(a)	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: <u>Feb. 16, 2007</u>	 Alan W. Steele, M.D., Ph.D., Registration No. 45,128

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Please enter the following amendment in the above-referenced application.

In response to the Restriction Requirement set forth in the Office Action mailed December 21, 2006, Applicant hereby provisionally elects Group I, claims 1-6, 7, and 17-18 for continued examination.

In response to the requirement to elect a single disclosed species set forth in the Office Action mailed December 21, 2006, Applicant further hereby provisionally elects PSA1 as a polymer, carboxyl as a negatively charged moiety, and antihistamine as an anti-allergy medicament.

Amendments to the claims begin on page 2 of this paper.

Remarks begin on page 4 of this paper.